PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1250772
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1250772
Huntington's Disease Treatment Market Forecasts to 2028 - Global Analysis By Treatment (Disease-modifying therapies and Symptomatic treatment), Drug, End User and By Geography
According to Stratistics MRC, the Global Huntington's Disease Treatment Market is accounted for $8.5 billion in 2022 and is expected to reach $18.7 billion by 2028 growing at a CAGR of 14.1% during the forecast period. Huntington's disease is a rare inherited disease that causes progressive breakdown of nerve cells in the brain, mainly affecting physical movements, emotions and cognitive abilities. It is a condition in which the nerve cells of the brain malfunction and create clumps of a protein called neurofibrillary tangles that affect movement, thinking, reasoning, moods, and more. It can cause uncontrolled movements or muscle twitches (chorea), changes in speech patterns, depression, anxiety, and personality changes.
According to the Huntington's disease Society of America (HDSA), there were approximately 41,000 symptomatic Americans in 2021, with over 200,000 individuals at risk of inheriting the disease.
Market Dynamics:
Driver:
The rising incidence of Huntington's disease
The rising incidence of Huntington's disease across the globe is one of the primary factors driving the market growth. The procedure is frequently used to stop uncontrollable jerking and writhing motion, which enhances quality of life. In addition, clinical trials, strong drug type pipeline and growing adoption of improved medical treatments and therapies are expected to fuel the market growth.
Restraint:
Lack of approved drugs and stringent regulatory policies
Currently, there are only two drugs approved for the treatment of chorea associated with this condition and these drugs can only manage or control the symptoms but cannot cure the disease. Companies across the globe need to clear strict regulatory hurdles for the approval of drugs. Such regulatory limits may impact market participants' preferences, resulting in slower market growth during the projection period.
Opportunity:
Growing research and development activities
There is a vast area of research and development for Huntington's disease treatment approaches because there is no effective treatment or medication. This is expected to significantly boost market growth during the forecast period. Moreover, the promising government initiatives that promote the development of new drugs are estimated to be another factor supporting the market growth.
Threat:
Limited availability of drugs
The number of licensed pharmaceuticals is limited due to tight policies and restrictions. It is anticipated that the market's expansion will be constrained by the lack of knowledge about this illness in many regions of the world. Many medications have failed to show efficacy or have been linked to significant toxicity, which has presented significant challenges for the discovery of drugs to treat the disease. This is expected to hamper the market growth.
Covid-19 Impact
The COVID-19 outbreak is projected to have a detrimental effect on the size of the market for treating Huntington's disease. To accommodate more patients with COVID-19, a sizable number of clinics and hospitals around the world underwent restructuring. Because of the sharp increase in patients, non-essential operations could be delayed. Production and delivery of supplies for healthcare were halted as a result of the lockdown. Lack of access to healthcare, a staffing deficit in the medical field, and an increase in COVID-19-related hospitalisation are some additional variables that have an impact on the market.
The disease-modifying therapies segment is expected to be the largest during the forecast period
The disease-modifying therapies segment is estimated to have a lucrative growth, due to an increase in disease-modifying therapy R&D. They can be administered intravenously or orally to lessen current symptoms or slow their progression. Disease-modifying therapies can help with problems like psychological illnesses and depression linked to this condition, but they have not been found to change patient mortality rates.
The antidepressants segment is expected to have the highest CAGR during the forecast period
The antidepressants segment is anticipated to witness the fastest CAGR growth during the forecast period, due to they are intended to restore the mental stability. Antidepressants are prescription medications that can help with symptoms of clinical depression, dysthymia, social anxiety, anxiety, and other conditions. Treatment with antidepressants focuses primarily on reducing the symptoms of severe depression. These are driving the segment growth.
Region with Largest share:
Asia Pacific is projected to hold the largest market share during the forecast period owing to the comparatively lower prevalence rate of this condition amongst the population. However, increasing awareness among the patient population toward available treatment along with improving reimbursement policies in these regions during the forecast period will contribute to their growth prospects.
Region with highest CAGR:
North America is projected to have the highest CAGR over the forecast period, owing to the increasing product penetration. A high level of public awareness about the condition, as well as growing support from numerous public and private organisations through research funding, to expedite the study of this disease. As governments take more initiatives to improve the health status of the populations, the market in the region is expected to grow.
Key Players in the market
Some of the key players profiled in the Huntington's Disease Treatment Market include Novartis AG, Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries, Inc., Lupin, Hetero, Hikma Pharmaceuticals PLC, Bausch Health Companies Inc., Alterity Therapeutics, H. Lundbeck A/S, Neurocrine Biosciences, Inc., Annexon Biosciences, PTC Therapeutics, Prilenia Therapeutics, Amneal Pharmaceuticals LLC., SOM BIOTECH and Vertex Pharmaceuticals Incorporated.
Key Developments:
In December 2021, Novartis AG received Fast Track designation for Branaplam from the FDA for Huntington's disease treatment. Branaplam is an mRNA splicing modulator that targets the HTT protein responsible for causing the degeneration of nerve cells leading to Huntington's disease.
In October 2021, Teva Pharmaceutical Industries Ltd. Received marketing approval for the treatment of chorea associated with Huntington's disease treatment and for the treatment of tardive dyskinesia in Brazil.
Treatments Covered:
- Disease-modifying therapies
- Symptomatic treatment
Drugs Covered:
- Antidepressants
- Antipsychotic Drugs
- Tranquilizers
- Tetrabenazine
- Other Drugs
End Users Covered:
- Clinics
- Hospital
- Retail Pharmacies
- Online Pharmacies
- Other End Users
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 End User Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Huntington's Disease Treatment Market, By Treatment
- 5.1 Introduction
- 5.2 Disease-modifying therapies
- 5.3 Symptomatic treatment
6 Global Huntington's Disease Treatment Market, By Drug
- 6.1 Introduction
- 6.2 Antidepressants
- 6.3 Antipsychotic Drugs
- 6.4 Tranquilizers
- 6.5 Tetrabenazine
- 6.6 Other Drugs
7 Global Huntington's Disease Treatment Market, By End User
- 7.1 Introduction
- 7.2 Clinics
- 7.3 Hospital
- 7.4 Retail Pharmacies
- 7.5 Online Pharmacies
- 7.6 Other End Users
8 Global Huntington's Disease Treatment Market, By Geography
- 8.1 Introduction
- 8.2 North America
- 8.2.1 US
- 8.2.2 Canada
- 8.2.3 Mexico
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 Italy
- 8.3.4 France
- 8.3.5 Spain
- 8.3.6 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 New Zealand
- 8.4.6 South Korea
- 8.4.7 Rest of Asia Pacific
- 8.5 South America
- 8.5.1 Argentina
- 8.5.2 Brazil
- 8.5.3 Chile
- 8.5.4 Rest of South America
- 8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 UAE
- 8.6.3 Qatar
- 8.6.4 South Africa
- 8.6.5 Rest of Middle East & Africa
9 Key Developments
- 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 9.2 Acquisitions & Mergers
- 9.3 New Product Launch
- 9.4 Expansions
- 9.5 Other Key Strategies
10 Company Profiling
- 10.1 Novartis AG
- 10.2 Teva Pharmaceutical Industries Ltd.
- 10.3 Dr. Reddy's Laboratories Ltd.
- 10.4 Sun Pharmaceutical Industries, Inc.
- 10.5 Lupin
- 10.6 Hetero
- 10.7 Hikma Pharmaceuticals PLC
- 10.8 Bausch Health Companies Inc.
- 10.9 Alterity Therapeutics
- 10.10 H. Lundbeck A/S
- 10.11 Neurocrine Biosciences, Inc.
- 10.12 Annexon Biosciences
- 10.13 PTC Therapeutics
- 10.14 Prilenia Therapeutics
- 10.15 Amneal Pharmaceuticals LLC.
- 10.16 SOM BIOTECH
- 10.17 Vertex Pharmaceuticals Incorporated
List of Tables
- Table 1 Global Huntington's Disease Treatment Market Outlook, By Region (2020-2028) ($MN)
- Table 2 Global Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
- Table 3 Global Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
- Table 4 Global Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
- Table 5 Global Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
- Table 6 Global Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
- Table 7 Global Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
- Table 8 Global Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
- Table 9 Global Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
- Table 10 Global Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
- Table 11 Global Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
- Table 12 Global Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
- Table 13 Global Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
- Table 14 Global Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
- Table 15 Global Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
- Table 16 Global Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
- Table 17 North America Huntington's Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
- Table 18 North America Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
- Table 19 North America Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
- Table 20 North America Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
- Table 21 North America Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
- Table 22 North America Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
- Table 23 North America Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
- Table 24 North America Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
- Table 25 North America Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
- Table 26 North America Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
- Table 27 North America Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
- Table 28 North America Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
- Table 29 North America Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
- Table 30 North America Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
- Table 31 North America Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
- Table 32 North America Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
- Table 33 Europe Huntington's Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
- Table 34 Europe Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
- Table 35 Europe Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
- Table 36 Europe Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
- Table 37 Europe Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
- Table 38 Europe Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
- Table 39 Europe Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
- Table 40 Europe Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
- Table 41 Europe Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
- Table 42 Europe Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
- Table 43 Europe Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
- Table 44 Europe Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
- Table 45 Europe Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
- Table 46 Europe Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
- Table 47 Europe Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
- Table 48 Europe Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
- Table 49 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
- Table 50 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
- Table 51 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
- Table 52 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
- Table 53 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
- Table 54 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
- Table 55 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
- Table 56 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
- Table 57 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
- Table 58 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
- Table 59 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
- Table 60 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
- Table 61 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
- Table 62 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
- Table 63 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
- Table 64 Asia Pacifiic Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
- Table 65 South America Huntington's Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
- Table 66 South America Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
- Table 67 South America Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
- Table 68 South America Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
- Table 69 South America Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
- Table 70 South America Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
- Table 71 South America Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
- Table 72 South America Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
- Table 73 South America Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
- Table 74 South America Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
- Table 75 South America Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
- Table 76 South America Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
- Table 77 South America Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
- Table 78 South America Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
- Table 79 South America Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
- Table 80 South America Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
- Table 81 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Country (2020-2028) ($MN)
- Table 82 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Treatment (2020-2028) ($MN)
- Table 83 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Disease-modifying therapies (2020-2028) ($MN)
- Table 84 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Symptomatic treatment (2020-2028) ($MN)
- Table 85 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Drug (2020-2028) ($MN)
- Table 86 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Antidepressants (2020-2028) ($MN)
- Table 87 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Antipsychotic Drugs (2020-2028) ($MN)
- Table 88 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Tranquilizers (2020-2028) ($MN)
- Table 89 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Tetrabenazine (2020-2028) ($MN)
- Table 90 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Other Drugs (2020-2028) ($MN)
- Table 91 Middle East & Africa Huntington's Disease Treatment Market Outlook, By End User (2020-2028) ($MN)
- Table 92 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Clinics (2020-2028) ($MN)
- Table 93 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Hospital (2020-2028) ($MN)
- Table 94 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
- Table 95 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Online Pharmacies (2020-2028) ($MN)
- Table 96 Middle East & Africa Huntington's Disease Treatment Market Outlook, By Other End Users (2020-2028) ($MN)
